Eva Harris Selected Research

Zika Virus Infection

1/2022	Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.
10/2021	The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking De Novo Formation of the Membranous Replication Compartment.
10/2021	Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term.
1/2021	Pre-existing T Cell Memory against Zika Virus.
1/2021	Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
1/2021	Persistence of Anti-ZIKV-IgG over Time Is Not a Useful Congenital Infection Marker in Infants Born to ZIKV-Infected Mothers: The NATZIG Cohort.
11/2020	Avian anti-NS1 IgY antibodies neutralize dengue virus infection and protect against lethal dengue virus challenge.
6/2020	Evaluation of ViroTrack Sero Zika IgG/IgM, a New Rapid and Quantitative Zika Serological Diagnostic Assay.
1/2020	Comprehensive Immunoprofiling of Pediatric Zika Reveals Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus Infection.
1/2020	Zika virus infection enhances future risk of severe dengue disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eva Harris Research Topics

Disease

116	Infections 04/2024 - 12/2002
85	Dengue (Dengue Fever) 04/2024 - 12/2002
27	Zika Virus Infection 01/2022 - 08/2016
18	Severe Dengue 01/2022 - 09/2007
10	COVID-19 12/2022 - 01/2021
10	Virus Diseases (Viral Diseases) 01/2022 - 12/2002
7	Fever (Fevers) 01/2020 - 08/2010
6	Yellow Fever 06/2023 - 03/2006
6	Flavivirus Infections 01/2022 - 12/2002
5	Human Influenza (Influenza) 01/2023 - 11/2009
5	Shock 01/2022 - 08/2009
4	Coinfection 05/2017 - 09/2010
3	Japanese Encephalitis 05/2022 - 01/2018
3	Microcephaly 01/2021 - 11/2017
2	Convalescence 10/2023 - 01/2018
2	Inflammation (Inflammations) 10/2023 - 01/2022
2	Leukopenia 01/2020 - 01/2012
2	Exanthema (Rash) 01/2020 - 01/2012
2	Headache (Headaches) 01/2020 - 01/2012
2	Pain (Aches) 01/2020 - 01/2012
2	Vomiting 01/2020 - 01/2012
2	Arthralgia (Joint Pain) 01/2020 - 01/2012
2	Myalgia 01/2020 - 01/2012
2	Guillain-Barre Syndrome 01/2019 - 01/2018
2	Hemorrhage 06/2017 - 01/2015
2	Mosquito-Borne Diseases 06/2013 - 12/2002
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Pneumonia (Pneumonitis) 01/2021
1	Congenital Abnormalities (Deformity) 01/2021
1	Rickettsia Infections 01/2021
1	Sepsis (Septicemia) 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Atherosclerosis 01/2021
1	Respiratory Syncytial Virus Infections 01/2020
1	Apnea 01/2020

Drug/Important Bio-Agent (IBA)

47	AntibodiesIBA 11/2023 - 03/2003
44	VaccinesIBA 04/2024 - 07/2009
31	Proteins (Proteins, Gene)FDA Link 04/2024 - 07/2005
18	Neutralizing AntibodiesIBA 01/2024 - 01/2011
15	Immunoglobulin G (IgG)IBA 04/2024 - 02/2004
15	Immunoglobulin M (IgM)IBA 01/2021 - 03/2003
12	Dengue VaccinesIBA 04/2024 - 01/2013
12	EnzymesIBA 01/2022 - 07/2005
12	Antiviral Agents (Antivirals)IBA 10/2021 - 12/2002
11	ImmunosorbentsIBA 01/2022 - 07/2005
10	EpitopesIBA 01/2021 - 09/2010
10	AntigensIBA 01/2021 - 08/2004
10	RNA (Ribonucleic Acid)IBA 01/2020 - 12/2002
9	CytokinesIBA 10/2023 - 06/2005
9	InterferonsIBA 06/2016 - 03/2004
8	Monoclonal AntibodiesIBA 08/2017 - 02/2010
7	Immune Sera (Antisera)IBA 01/2022 - 01/2013
7	Peptides (Polypeptides)IBA 01/2018 - 08/2004
6	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022 - 06/2007
5	Glycoproteins (Glycoprotein)IBA 11/2023 - 10/2008
5	Blocking AntibodiesIBA 10/2021 - 02/2013
5	Viral RNAIBA 01/2021 - 12/2002
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
3	Immunologic Factors (Immunomodulators)IBA 01/2023 - 03/2004
3	Nucleic AcidsIBA 01/2022 - 06/2010
3	Interferon Receptors (Interferon Receptor)IBA 01/2021 - 10/2006
3	Attenuated VaccinesIBA 01/2020 - 01/2017
3	Explosive Agents (Explosives)IBA 01/2018 - 11/2017
3	Indicators and Reagents (Reagents)IBA 09/2007 - 07/2005
2	Caspase 1 (ICE Protease)IBA 04/2024 - 09/2023
2	InflammasomesIBA 04/2024 - 09/2023
2	ChemokinesIBA 10/2023 - 01/2020
2	ProteomeIBA 10/2023 - 01/2018
2	COVID-19 VaccinesIBA 01/2022 - 01/2021
2	oxidized low density lipoproteinIBA 01/2022 - 01/2015
2	IgYIBA 11/2020 - 07/2017
2	Broadly Neutralizing AntibodiesIBA 01/2020 - 05/2017
2	Combined VaccinesIBA 01/2018 - 01/2012
2	PesticidesIBA 01/2017 - 01/2017
2	GlucosidasesIBA 05/2016 - 03/2016
2	Interferon-betaIBA 10/2012 - 03/2004
2	Immunoglobulin A (IgA)IBA 11/2008 - 03/2003
2	Interleukin-10 (Interleukin 10)IBA 10/2008 - 06/2005
1	Syndecan-1 (Syndecan 1)IBA 06/2023
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2023
1	IntegrinsIBA 12/2022
1	cadherin 5IBA 05/2022
1	CateninsIBA 05/2022
1	Lipoproteins (Lipoprotein)IBA 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022
1	MucinsIBA 01/2022
1	PlasticsIBA 01/2022
1	GlucansIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2021
1	Conjugate VaccinesIBA 01/2021
1	Virulence Factors (Pathogenicity Factors)IBA 01/2021
1	SyndecansIBA 01/2021
1	Hyaluronic Acid (Hyaluronan)IBA 01/2021

Therapy/Procedure

15	Therapeutics 12/2022 - 12/2002
2	Tourniquets 01/2020 - 01/2012
1	Microspheres (Microsphere) 04/2024
1	Length of Stay 02/2024
1	Lab-On-A-Chip Devices 01/2022
1	Intranasal Administration 01/2022